{"protocolSection": {"identificationModule": {"nctId": "NCT02554890", "orgStudyIdInfo": {"id": "CLCZ696BUS01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.", "officialTitle": "A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).", "acronym": "PIONEER-HF"}, "statusModule": {"statusVerifiedDate": "2020-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-04-29", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-06-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-07-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-09-17", "studyFirstSubmitQcDate": "2015-09-17", "studyFirstPostDateStruct": {"date": "2015-09-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-07-19", "resultsFirstSubmitQcDate": "2019-09-03", "resultsFirstPostDateStruct": {"date": "2019-09-24", "type": "ACTUAL"}, "dispFirstSubmitDate": "2019-01-16", "dispFirstSubmitQcDate": "2019-01-16", "dispFirstPostDateStruct": {"date": "2019-01-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-12-09", "lastUpdatePostDateStruct": {"date": "2021-01-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) \u2264 40%)."}, "conditionsModule": {"conditions": ["Acute Heart Failure"], "keywords": ["Acute", "Heart Failure", "reduced ejection fraction", "NTproBNP", "Heart failure with reduced ejection fraction (HFREF)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "SUPPORTIVE_CARE", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 887, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "sacubitril/valsartan (LCZ696)", "type": "EXPERIMENTAL", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).", "interventionNames": ["Drug: sacubitril/valsartan (LCZ696)", "Drug: enalapril matching placebo"]}, {"label": "Enalapril", "type": "ACTIVE_COMPARATOR", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)", "interventionNames": ["Drug: Enalapril", "Drug: sacubitril/valsartan (LCZ696) matching placebo"]}], "interventions": [{"type": "DRUG", "name": "sacubitril/valsartan (LCZ696)", "description": "sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.", "armGroupLabels": ["sacubitril/valsartan (LCZ696)"], "otherNames": ["LCZ696"]}, {"type": "DRUG", "name": "Enalapril", "description": "Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.", "armGroupLabels": ["Enalapril"]}, {"type": "DRUG", "name": "sacubitril/valsartan (LCZ696) matching placebo", "description": "matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.", "armGroupLabels": ["Enalapril"]}, {"type": "DRUG", "name": "enalapril matching placebo", "description": "enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.", "armGroupLabels": ["sacubitril/valsartan (LCZ696)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline", "description": "To assess the effect of in-hospital initiation of sacubitril/valsartan vs. enalapril on the time-averaged percentage change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for ADHF and reduced ejection fraction (left ventricular ejection fraction \\[LVEF\\] \u2264 40%) between week 4 and 8.\n\nNumber of patients with both a baseline value and a value at Week 4 or Week 8. Plasma NT-proBNP (pg/mL) values were averaged from Week 4 and Week 8 visits. N-terminal pro b-type natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.", "timeFrame": "Baseline, Week 4 and Week 8"}], "secondaryOutcomes": [{"measure": "Number of Patients With Incidences of Symptomatic Hypotension", "description": "Examine the effect of LCZ696 vs. enalapril on incidence of symptomatic hypotension during 8 weeks of treatment Hypotension is low blood pressure. Patients with hypotension may experience symptoms when their blood pressure drops, compared to the patient's normal values. Symptoms of hypotension can include dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache.", "timeFrame": "8 weeks of treatment"}, {"measure": "Number of Patients With Incidences of Hyperkalemia", "description": "Hyperkalemia is defined as Potassium level \\>5.5 mEq/L. Hyperkalemia is the medical term that describes a potassium level in your blood that's higher than normal. Potassium is a chemical that is critical to the function of nerve and muscle cells, including those in your heart.", "timeFrame": "8 weeks of treatment"}, {"measure": "Number of Patients With Incidences of Angioedema", "description": "Angioedema is a type of abrupt swelling that occurs under the skin and/or mucous membranes and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, including the genitalia and intestines. Severe cases may be associated with difficulty in breathing.", "timeFrame": "8 weeks of treatment"}, {"measure": "Change From Baseline in High Sensitivity Troponin (Hs-Troponin)", "description": "time-averaged (Weeks 4 and 8) change from baseline in hs-troponin T. hs-Troponin-T is a biomarker that is released from the heart under stress or injury conditions.", "timeFrame": "Baseline, Week 4/Week 8"}, {"measure": "Change From Baseline in Urinary cGMP", "description": "Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP. Urinary Cyclic GMP (cGMP) is a biomarker measured in the urine that reflects the activity of biomarkers such as BNP (Brain Natriuretic Peptide)", "timeFrame": "Baseline, Week 4 and Week 8"}, {"measure": "Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio", "description": "Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP to urinary creatinine ratio.\n\nUrinary cGMP to urinary creatinine ratio is how much urinary cGMP (which reflects natriuretic peptide activity) compared to a compound in the urine called creatinine (which helps your doctor evaluate how well your kidneys are functioning).", "timeFrame": "Baseline, Week 4 and Week 8"}, {"measure": "Change From Baseline in BNP to NTproBNP Ratio", "description": "Time-averaged (Weeks 4 and 8) change from baseline in BNP to NT-proBNP ratio. BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.", "timeFrame": "baseline, Week 4 and Week 8"}, {"measure": "N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8", "description": "BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.\n\nPlasma NT-proBNP (pg/mL) values were Week 8 visit.", "timeFrame": "Baseline, Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Possess the capacity to provide written informed consent which must be obtained before any assessment is performed.\n2. Currently hospitalized for ADHF. Patients with a diagnosis of acute heart failure had to have symptoms and signs of fluid overload (i.e. jugular venous distention, edema or rales on auscultation or pulmonary congestion on chest x-ray) at time of hospitalization.\n3. Eligible patients will be randomized no earlier than 24 hours and up to ten days after presentation while still hospitalized as long as meet the following definition of stable status:\n\n   * SBP \u2265100mm Hg for the preceding 6 hours prior to randomization; no symptomatic hypotension\n   * No increase (intensification) in i.v. diuretic dose within last 6 hours prior to randomization\n   * No i.v. inotropic drugs for 24 hours prior to randomization\n   * No i.v. vasodilators including nitrates within last 6 hours prior to randomization\n4. LVEF \u226440% within the past 6 months (including current hospitalization) using echocardiography, multi gated acquisition scan (MUGA), CT scanning, MRI or ventricular angiography, provided no subsequent study documented an EF of \\>40%.\n5. Elevated NT-proBNP \u2265 1600pg/mL OR BNP \u2265400 pg/mL during current hospitalization.\n\nKey Exclusion Criteria:\n\n1. Currently taking sacubitril/valsartan tablets or any use within the past 30 days.\n2. Enrollment in any other clinical trial involving an investigational agent or investigational device.\n3. History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs, including ACEIs, ARBs, or Sacubitril (NEP inhibitor).\n4. Patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy.\n5. Requirement of treatment with both ACE inhibitor and ARB.\n6. eGFR \\< 30 ml/min/1.73 m2 as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at screening.\n7. Serum potassium \\> 5.2 mEq/L at screening.\n8. Known hepatic impairment (as evidenced by total bilirubin \\> 3 mg/dL, or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as varices\n9. Acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid or other major CV surgery; percutaneous coronary intervention (PCI) or carotid angioplasty, within one month prior to Visit 1.\n10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.\n11. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Birmingham", "state": "Alabama", "zip": "35294", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Novartis Investigative Site", "city": "Fort Smith", "state": "Arkansas", "zip": "72901", "country": "United States", "geoPoint": {"lat": 35.38592, "lon": -94.39855}}, {"facility": "Novartis Investigative Site", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Novartis Investigative Site", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Novartis Investigative Site", "city": "Fresno", "state": "California", "zip": "93701", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Novartis Investigative Site", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Novartis Investigative Site", "city": "Los Angeles", "state": "California", "zip": "90033", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigative Site", "city": "Los Angeles", "state": "California", "zip": "90073", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigative Site", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Novartis Investigative Site", "city": "Pasadena", "state": "California", "zip": "91105", "country": "United States", "geoPoint": {"lat": 34.14778, "lon": -118.14452}}, {"facility": "Novartis Investigative Site", "city": "Sacramento", "state": "California", "zip": "95817-1460", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Novartis Investigative Site", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigative Site", "city": "San Marino", "state": "California", "zip": "91108", "country": "United States", "geoPoint": {"lat": 34.1214, "lon": -118.10646}}, {"facility": "Novartis Investigative Site", "city": "San Pablo", "state": "California", "zip": "94806", "country": "United States", "geoPoint": {"lat": 37.96215, "lon": -122.34553}}, {"facility": "Novartis Investigative Site", "city": "Stanford", "state": "California", "zip": "94305", "country": "United States", "geoPoint": {"lat": 37.42411, "lon": -122.16608}}, {"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Littleton", "state": "Colorado", "zip": "80120", "country": "United States", "geoPoint": {"lat": 39.61332, "lon": -105.01665}}, {"facility": "Novartis Investigative Site", "city": "Bridgeport", "state": "Connecticut", "zip": "06610", "country": "United States", "geoPoint": {"lat": 41.16704, "lon": -73.20483}}, {"facility": "Novartis Investigative Site", "city": "Hartford", "state": "Connecticut", "zip": "06102", "country": "United States", "geoPoint": {"lat": 41.76371, "lon": -72.68509}}, {"facility": "Novartis Investigative Site", "city": "Hartford", "state": "Connecticut", "zip": "06105", "country": "United States", "geoPoint": {"lat": 41.76371, "lon": -72.68509}}, {"facility": "Novartis Investigative Site", "city": "West Haven", "state": "Connecticut", "zip": "06516", "country": "United States", "geoPoint": {"lat": 41.27065, "lon": -72.94705}}, {"facility": "Novartis Investigative Site", "city": "Washington", "state": "District of Columbia", "zip": "20422", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Novartis Investigative Site", "city": "Atlantis", "state": "Florida", "zip": "33462", "country": "United States", "geoPoint": {"lat": 26.5909, "lon": -80.10088}}, {"facility": "Novartis Investigative Site", "city": "Daytona Beach", "state": "Florida", "zip": "32117", "country": "United States", "geoPoint": {"lat": 29.21081, "lon": -81.02283}}, {"facility": "Novartis Investigative Site", "city": "Fort Lauderdale", "state": "Florida", "zip": "33308", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "Novartis Investigative Site", "city": "Gainesville", "state": "Florida", "zip": "32608", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Novartis Investigative Site", "city": "Gainesville", "state": "Florida", "zip": "32610", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Novartis Investigative Site", "city": "Hollywood", "state": "Florida", "zip": "33021", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "Novartis Investigative Site", "city": "Jacksonville", "state": "Florida", "zip": "32209-6511", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Novartis Investigative Site", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Novartis Investigative Site", "city": "Lakeland", "state": "Florida", "zip": "33805", "country": "United States", "geoPoint": {"lat": 28.03947, "lon": -81.9498}}, {"facility": "Novartis Investigative Site", "city": "Sarasota", "state": "Florida", "zip": "34239", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Novartis Investigative Site", "city": "Tampa", "state": "Florida", "zip": "33612", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Novartis Investigative Site", "city": "Tampa", "state": "Florida", "zip": "34667", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Novartis Investigative Site", "city": "Vero Beach", "state": "Florida", "zip": "32960", "country": "United States", "geoPoint": {"lat": 27.63864, "lon": -80.39727}}, {"facility": "Novartis Investigative Site", "city": "Winter Haven", "state": "Florida", "zip": "33881", "country": "United States", "geoPoint": {"lat": 28.02224, "lon": -81.73286}}, {"facility": "Novartis Investigative Site", "city": "Augusta", "state": "Georgia", "zip": "30901", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "Novartis Investigative Site", "city": "Macon", "state": "Georgia", "zip": "31201", "country": "United States", "geoPoint": {"lat": 32.84069, "lon": -83.6324}}, {"facility": "Novartis Investigative Site", "city": "Marietta", "state": "Georgia", "zip": "30060", "country": "United States", "geoPoint": {"lat": 33.9526, "lon": -84.54993}}, {"facility": "Novartis Investigative Site", "city": "Boise", "state": "Idaho", "zip": "83702", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Novartis Investigative Site", "city": "Aurora", "state": "Illinois", "zip": "60504", "country": "United States", "geoPoint": {"lat": 41.76058, "lon": -88.32007}}, {"facility": "Novartis Investigative Site", "city": "Elk Grove Village", "state": "Illinois", "zip": "60007", "country": "United States", "geoPoint": {"lat": 42.00392, "lon": -87.97035}}, {"facility": "Novartis Investigative Site", "city": "Oakbrook Terrace", "state": "Illinois", "zip": "60181", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.96451}}, {"facility": "Novartis Investigative Site", "city": "Park Ridge", "state": "Illinois", "zip": "60068", "country": "United States", "geoPoint": {"lat": 42.01114, "lon": -87.84062}}, {"facility": "Novartis Investigative Site", "city": "Peoria", "state": "Illinois", "zip": "61606", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Novartis Investigative Site", "city": "Peoria", "state": "Illinois", "zip": "61614", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Novartis Investigative Site", "city": "Winfield", "state": "Illinois", "zip": "60190", "country": "United States", "geoPoint": {"lat": 41.8617, "lon": -88.1609}}, {"facility": "Novartis Investigative Site", "city": "Elkhart", "state": "Indiana", "zip": "46514", "country": "United States", "geoPoint": {"lat": 41.68199, "lon": -85.97667}}, {"facility": "Novartis Investigative Site", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Novartis Investigative Site", "city": "Indianapolis", "state": "Indiana", "zip": "46237", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Novartis Investigative Site", "city": "Muncie", "state": "Indiana", "zip": "47303-3400", "country": "United States", "geoPoint": {"lat": 40.19338, "lon": -85.38636}}, {"facility": "Novartis Investigative Site", "city": "Richmond", "state": "Indiana", "zip": "47374", "country": "United States", "geoPoint": {"lat": 39.82894, "lon": -84.89024}}, {"facility": "Novartis Investigative Site", "city": "Des Moines", "state": "Iowa", "zip": "50314", "country": "United States", "geoPoint": {"lat": 41.60054, "lon": -93.60911}}, {"facility": "Novartis Investigative Site", "city": "Kansas City", "state": "Kansas", "zip": "66103", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "Novartis Investigative Site", "city": "Louisville", "state": "Kentucky", "zip": "40205", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Novartis Investigative Site", "city": "Louisville", "state": "Kentucky", "zip": "40245", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Novartis Investigative Site", "city": "Alexandria", "state": "Louisiana", "zip": "71301", "country": "United States", "geoPoint": {"lat": 31.31129, "lon": -92.44514}}, {"facility": "Novartis Investigative Site", "city": "Baton Rouge", "state": "Louisiana", "zip": "70808", "country": "United States", "geoPoint": {"lat": 30.45075, "lon": -91.15455}}, {"facility": "Novartis Investigative Site", "city": "Slidell", "state": "Louisiana", "zip": "70458", "country": "United States", "geoPoint": {"lat": 30.27519, "lon": -89.78117}}, {"facility": "Novartis Investigative Site", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Novartis Investigative Site", "city": "Annapolis", "state": "Maryland", "zip": "21401", "country": "United States", "geoPoint": {"lat": 38.97845, "lon": -76.49218}}, {"facility": "Novartis Investigative Site", "city": "Baltimore", "state": "Maryland", "zip": "21215", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novartis Investigative Site", "city": "Boston", "state": "Massachusetts", "zip": "02215", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Novartis Investigative Site", "city": "Boston", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Novartis Investigative Site", "city": "Ann Arbor", "state": "Michigan", "zip": "48106", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Novartis Investigative Site", "city": "Bay City", "state": "Michigan", "zip": "48708", "country": "United States", "geoPoint": {"lat": 43.59447, "lon": -83.88886}}, {"facility": "Novartis Investigative Site", "city": "Detroit", "state": "Michigan", "zip": "48201", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Novartis Investigative Site", "city": "Maplewood", "state": "Minnesota", "zip": "55109", "country": "United States", "geoPoint": {"lat": 44.95302, "lon": -92.99522}}, {"facility": "Novartis Investigative Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55417", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Novartis Investigative Site", "city": "Saint Paul", "state": "Minnesota", "zip": "55101", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "Novartis Investigative Site", "city": "Saint Paul", "state": "Minnesota", "zip": "55102", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "Novartis Investigative Site", "city": "Hattiesburg", "state": "Mississippi", "zip": "39401", "country": "United States", "geoPoint": {"lat": 31.32712, "lon": -89.29034}}, {"facility": "Novartis Investigative Site", "city": "Jackson", "state": "Mississippi", "zip": "39216", "country": "United States", "geoPoint": {"lat": 32.29876, "lon": -90.18481}}, {"facility": "Novartis Investigative Site", "city": "Kansas City", "state": "Missouri", "zip": "64108", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Novartis Investigative Site", "city": "Omaha", "state": "Nebraska", "zip": "68198", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigative Site", "city": "Reno", "state": "Nevada", "zip": "89502", "country": "United States", "geoPoint": {"lat": 39.52963, "lon": -119.8138}}, {"facility": "Novartis Investigative Site", "city": "Camden", "state": "New Jersey", "zip": "08103-3117", "country": "United States", "geoPoint": {"lat": 39.92595, "lon": -75.11962}}, {"facility": "Novartis Investigative Site", "city": "Elmer", "state": "New Jersey", "zip": "08318", "country": "United States", "geoPoint": {"lat": 39.59511, "lon": -75.17018}}, {"facility": "Novartis Investigative Site", "city": "Haddon Heights", "state": "New Jersey", "zip": "08035", "country": "United States", "geoPoint": {"lat": 39.87734, "lon": -75.06462}}, {"facility": "Novartis Investigative Site", "city": "Newark", "state": "New Jersey", "zip": "07102", "country": "United States", "geoPoint": {"lat": 40.73566, "lon": -74.17237}}, {"facility": "Novartis Investigative Site", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Novartis Investigative Site", "city": "Bronx", "state": "New York", "zip": "10467-2490", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Novartis Investigative Site", "city": "Brooklyn", "state": "New York", "zip": "11215", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Novartis Investigative Site", "city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Novartis Investigative Site", "city": "Johnson City", "state": "New York", "zip": "13790", "country": "United States", "geoPoint": {"lat": 42.11563, "lon": -75.95881}}, {"facility": "Novartis Investigative Site", "city": "Manhasset", "state": "New York", "zip": "11030", "country": "United States", "geoPoint": {"lat": 40.79788, "lon": -73.69957}}, {"facility": "Novartis Investigative Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Novartis Investigative Site", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Novartis Investigative Site", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Novartis Investigative Site", "city": "Poughkeepsie", "state": "New York", "zip": "12601", "country": "United States", "geoPoint": {"lat": 41.70037, "lon": -73.92097}}, {"facility": "Novartis Investigative Site", "city": "Rochester", "state": "New York", "zip": "14621", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Novartis Investigative Site", "city": "Staten Island", "state": "New York", "zip": "10310", "country": "United States", "geoPoint": {"lat": 40.56233, "lon": -74.13986}}, {"facility": "Novartis Investigative Site", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Novartis Investigative Site", "city": "Greenville", "state": "North Carolina", "zip": "27834", "country": "United States", "geoPoint": {"lat": 35.61266, "lon": -77.36635}}, {"facility": "Novartis Investigative Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Novartis Investigative Site", "city": "Grand Forks", "state": "North Dakota", "zip": "58201", "country": "United States", "geoPoint": {"lat": 47.92526, "lon": -97.03285}}, {"facility": "Novartis Investigative Site", "city": "Cincinnati", "state": "Ohio", "zip": "45220", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigative Site", "city": "Toledo", "state": "Ohio", "zip": "43608", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Novartis Investigative Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73122", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigative Site", "city": "Tulsa", "state": "Oklahoma", "zip": "74104", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Novartis Investigative Site", "city": "Abington", "state": "Pennsylvania", "zip": "19001", "country": "United States", "geoPoint": {"lat": 40.12067, "lon": -75.11795}}, {"facility": "Novartis Investigative Site", "city": "Camp Hill", "state": "Pennsylvania", "zip": "17011", "country": "United States", "geoPoint": {"lat": 40.23981, "lon": -76.91997}}, {"facility": "Novartis Investigative Site", "city": "Natrona Heights", "state": "Pennsylvania", "zip": "15065", "country": "United States", "geoPoint": {"lat": 40.6234, "lon": -79.72977}}, {"facility": "Novartis Investigative Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19102 2293", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Novartis Investigative Site", "city": "Providence", "state": "Rhode Island", "zip": "02903", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Novartis Investigative Site", "city": "Charleston", "state": "South Carolina", "zip": "29403", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Novartis Investigative Site", "city": "Greenville", "state": "South Carolina", "zip": "29615", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Novartis Investigative Site", "city": "Rapid City", "state": "South Dakota", "zip": "57701", "country": "United States", "geoPoint": {"lat": 44.08054, "lon": -103.23101}}, {"facility": "Novartis Investigative Site", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Novartis Investigative Site", "city": "Nashville", "state": "Tennessee", "zip": "37212", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Novartis Investigative Site", "city": "Dallas", "state": "Texas", "zip": "75204", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigative Site", "city": "Dallas", "state": "Texas", "zip": "75390", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Novartis Investigative Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Novartis Investigative Site", "city": "White River Junction", "state": "Vermont", "zip": "05009", "country": "United States", "geoPoint": {"lat": 43.64896, "lon": -72.31926}}, {"facility": "Novartis Investigative Site", "city": "Charlottesville", "state": "Virginia", "zip": "22908", "country": "United States", "geoPoint": {"lat": 38.02931, "lon": -78.47668}}, {"facility": "Novartis Investigative Site", "city": "Lynchburg", "state": "Virginia", "zip": "24501", "country": "United States", "geoPoint": {"lat": 37.41375, "lon": -79.14225}}, {"facility": "Novartis Investigative Site", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Novartis Investigative Site", "city": "Virginia Beach", "state": "Virginia", "zip": "23454", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "Novartis Investigative Site", "city": "Clarksburg", "state": "West Virginia", "zip": "26301", "country": "United States", "geoPoint": {"lat": 39.28065, "lon": -80.34453}}, {"facility": "Novartis Investigative Site", "city": "Madison", "state": "Wisconsin", "zip": "53792-1615", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Novartis Investigative Site", "city": "Wausau", "state": "Wisconsin", "zip": "54401", "country": "United States", "geoPoint": {"lat": 44.95914, "lon": -89.63012}}]}, "referencesModule": {"references": [{"pmid": "29653636", "type": "BACKGROUND", "citation": "Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 Apr;198:145-151. doi: 10.1016/j.ahj.2018.01.004. Epub 2018 Jan 10."}, {"pmid": "30415601", "type": "BACKGROUND", "citation": "Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum In: N Engl J Med. 2019 Mar 14;380(11):1090. doi: 10.1056/NEJMx190009."}, {"pmid": "30955360", "type": "BACKGROUND", "citation": "Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331. No abstract available."}, {"pmid": "31093657", "type": "BACKGROUND", "citation": "Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019 Oct 21;40(40):3345-3352. doi: 10.1093/eurheartj/ehz240."}, {"pmid": "32919915", "type": "DERIVED", "citation": "Berardi C, Braunwald E, Morrow DA, Mulder HS, Duffy CI, O'Brien TX, Ambrosy AP, Chakraborty H, Velazquez EJ, DeVore AD; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 Oct;8(10):859-866. doi: 10.1016/j.jchf.2020.06.019. Epub 2020 Sep 9."}, {"pmid": "32854838", "type": "DERIVED", "citation": "Ambrosy AP, Braunwald E, Morrow DA, DeVore AD, McCague K, Meng X, Duffy CI, Rocha R, Velazquez EJ; PIONEER-HF Investigators. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 Sep 1;76(9):1034-1048. doi: 10.1016/j.jacc.2020.06.073."}, {"pmid": "32800511", "type": "DERIVED", "citation": "Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail. 2020 Oct;8(10):834-843. doi: 10.1016/j.jchf.2020.06.008. Epub 2020 Aug 12."}, {"pmid": "31825471", "type": "DERIVED", "citation": "DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ; PIONEER-HF Investigators. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 Feb 1;5(2):202-207. doi: 10.1001/jamacardio.2019.4665."}], "seeAlsoLinks": [{"label": "A Plain Language Trial Summary is available on novartisclinicatrials.com", "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=338"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients were randomized 1:1 to sacubitril/valsartan or enalapril. At the end of the 8-week treatment period, all patients had a 36-hour washout from study treatment prior to starting the open-label extension to ensure that the blinding of the core study was maintained.", "recruitmentDetails": "A total of 964 patients were screened for the study. Of these, 887 patients were randomized, 444 to enalapril and 443 to sacubitril/valsartan, and 875 randomized patients were treated.", "groups": [{"id": "FG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "FG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "periods": [{"title": "Double-blind", "milestones": [{"type": "STARTED", "comment": "Randomized", "achievements": [{"groupId": "FG000", "numSubjects": "444"}, {"groupId": "FG001", "numSubjects": "443"}]}, {"type": "Treated Patients", "comment": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "436"}, {"groupId": "FG001", "numSubjects": "439"}]}, {"type": "COMPLETED", "comment": "Continued study treatment during double-blind phase", "achievements": [{"groupId": "FG000", "numSubjects": "348"}, {"groupId": "FG001", "numSubjects": "352"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "96"}, {"groupId": "FG001", "numSubjects": "91"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "51"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Subject/Guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Technical problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Noncompliance with study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}]}, {"title": "Open-label", "milestones": [{"type": "STARTED", "comment": "Randomized", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "887"}]}, {"type": "COMPLETED", "comment": "Continued study treatment during open-label phase", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "835"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "52"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Subject/Guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Technical problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Demographic and baseline characteristics are in the Full analysis set (FAS) of treatment groups.\n\nFAS: Patients who were randomized except those who were not qualified for randomization and have not received study treatment, but were inadvertently randomized.", "groups": [{"id": "BG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "BG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "441"}, {"groupId": "BG001", "value": "440"}, {"groupId": "BG002", "value": "881"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "232"}, {"groupId": "BG001", "value": "253"}, {"groupId": "BG002", "value": "485"}]}]}, {"title": "\u226565 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "187"}, {"groupId": "BG002", "value": "396"}]}]}, {"title": "< 75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "363"}, {"groupId": "BG001", "value": "370"}, {"groupId": "BG002", "value": "733"}]}]}, {"title": "\u226575 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "78"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "148"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "133"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "246"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "308"}, {"groupId": "BG001", "value": "327"}, {"groupId": "BG002", "value": "635"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "75"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "399"}, {"groupId": "BG001", "value": "405"}, {"groupId": "BG002", "value": "804"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline", "description": "To assess the effect of in-hospital initiation of sacubitril/valsartan vs. enalapril on the time-averaged percentage change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for ADHF and reduced ejection fraction (left ventricular ejection fraction \\[LVEF\\] \u2264 40%) between week 4 and 8.\n\nNumber of patients with both a baseline value and a value at Week 4 or Week 8. Plasma NT-proBNP (pg/mL) values were averaged from Week 4 and Week 8 visits. N-terminal pro b-type natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.", "populationDescription": "Full analysis set (FAS): consisted of all randomized patients with the exception for those patients who had not been qualified for randomization and had not received study treatment, but had been inadvertently randomized into the study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/ml", "timeFrame": "Baseline, Week 4 and Week 8", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.7466", "lowerLimit": "0.6842", "upperLimit": "0.8147"}, {"groupId": "OG001", "value": "0.5333", "lowerLimit": "0.4890", "upperLimit": "0.5816"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<.0001", "pValueComment": "ANCOVA model for a log-scaled response with treatment group as a class variable and biomarker baseline value in logarithmic scale as a continuous covariate.", "statisticalMethod": "ANCOVA", "paramType": "expon. back transformed from LS means", "paramValue": "0.7143", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.6315", "ciUpperLimit": "0.8080", "estimateComment": "Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril"}]}, {"type": "SECONDARY", "title": "Number of Patients With Incidences of Symptomatic Hypotension", "description": "Examine the effect of LCZ696 vs. enalapril on incidence of symptomatic hypotension during 8 weeks of treatment Hypotension is low blood pressure. Patients with hypotension may experience symptoms when their blood pressure drops, compared to the patient's normal values. Symptoms of hypotension can include dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks of treatment", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "66"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Incidences of Hyperkalemia", "description": "Hyperkalemia is defined as Potassium level \\>5.5 mEq/L. Hyperkalemia is the medical term that describes a potassium level in your blood that's higher than normal. Potassium is a chemical that is critical to the function of nerve and muscle cells, including those in your heart.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks of treatment", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "51"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Incidences of Angioedema", "description": "Angioedema is a type of abrupt swelling that occurs under the skin and/or mucous membranes and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, including the genitalia and intestines. Severe cases may be associated with difficulty in breathing.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks of treatment", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in High Sensitivity Troponin (Hs-Troponin)", "description": "time-averaged (Weeks 4 and 8) change from baseline in hs-troponin T. hs-Troponin-T is a biomarker that is released from the heart under stress or injury conditions.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Week 4/Week 8", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.7477", "lowerLimit": "0.6979", "upperLimit": "0.8010"}, {"groupId": "OG001", "value": "0.6345", "lowerLimit": "0.5920", "upperLimit": "0.6801"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.0011", "statisticalMethod": "ANCOVA", "paramType": "exponentially back transformed from LS m", "paramValue": "0.8487", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.7694", "ciUpperLimit": "0.9361", "estimateComment": "Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Urinary cGMP", "description": "Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP. Urinary Cyclic GMP (cGMP) is a biomarker measured in the urine that reflects the activity of biomarkers such as BNP (Brain Natriuretic Peptide)", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Week 4 and Week 8", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9641", "lowerLimit": "0.8832", "upperLimit": "1.0524"}, {"groupId": "OG001", "value": "1.5895", "lowerLimit": "1.4554", "upperLimit": "1.7359"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<.0001", "statisticalMethod": "ANCOVA", "paramType": "expon. back transformed from LS means", "paramValue": "1.6487", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.4559", "ciUpperLimit": "1.8669", "estimateComment": "Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio", "description": "Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP to urinary creatinine ratio.\n\nUrinary cGMP to urinary creatinine ratio is how much urinary cGMP (which reflects natriuretic peptide activity) compared to a compound in the urine called creatinine (which helps your doctor evaluate how well your kidneys are functioning).", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Week 4 and Week 8", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.8258", "lowerLimit": "0.7870", "upperLimit": "0.8665"}, {"groupId": "OG001", "value": "1.1714", "lowerLimit": "1.1160", "upperLimit": "1.2296"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<.0001", "statisticalMethod": "ANCOVA", "paramType": "expon. back transformed from LS means", "paramValue": "1.4186", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.3248", "ciUpperLimit": "1.5190", "estimateComment": "Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril"}]}, {"type": "SECONDARY", "title": "Change From Baseline in BNP to NTproBNP Ratio", "description": "Time-averaged (Weeks 4 and 8) change from baseline in BNP to NT-proBNP ratio. BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "baseline, Week 4 and Week 8", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9174", "lowerLimit": "0.8728", "upperLimit": "0.9642"}, {"groupId": "OG001", "value": "1.3527", "lowerLimit": "1.2882", "upperLimit": "1.4204"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<.0001", "statisticalMethod": "ANCOVA", "paramType": "expon. back transformed from LS means", "paramValue": "1.4745", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.3752", "ciUpperLimit": "1.5810", "estimateComment": "Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril"}]}, {"type": "SECONDARY", "title": "N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8", "description": "BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.\n\nPlasma NT-proBNP (pg/mL) values were Week 8 visit.", "populationDescription": "Full analysis set (FAS): consisted of all randomized patients with the exception for those patients who had not been qualified for randomization and had not received study treatment, but had been inadvertently randomized into the study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/ml", "timeFrame": "Baseline, Week 8", "groups": [{"id": "OG000", "title": "Enalapril", "description": "Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.\n\nPatients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"}, {"id": "OG001", "title": "Sacubitril/Valsartan (LCZ696)", "description": "Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6443", "lowerLimit": "0.5815", "upperLimit": "0.7410"}, {"groupId": "OG001", "value": "0.4596", "lowerLimit": "0.4150", "upperLimit": "0.5089"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<.0001", "pValueComment": "ANCOVA model for a log-scaled response with treatment group as a class variable and biomarker baseline value in logarithmic scale as a continuous covariate.", "statisticalMethod": "ANCOVA", "paramType": "expon. back transformed from LS means", "paramValue": "0.7133", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.6171", "ciUpperLimit": "0.8245", "estimateComment": "Geometric Mean Ratio: Sacubitril/Valsartan vs. Enalapril"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 85 days.", "description": "All cause mortality (deaths) was collected for as long as participants could be contacted from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV) up to a maximum of 85 days.\n\nData reported on the safety population.", "eventGroups": [{"id": "EG000", "title": "Double Blind Phase Enalapril", "description": "Patients who received Enalapril in the double-blind phase.", "deathsNumAffected": 15, "deathsNumAtRisk": 436, "seriousNumAffected": 132, "seriousNumAtRisk": 436, "otherNumAffected": 139, "otherNumAtRisk": 436}, {"id": "EG001", "title": "Double Blind Phase Sacubitril/Valsartan", "description": "Patients who received Sacubitril/Valsartan in the double-blind phase.", "deathsNumAffected": 10, "deathsNumAtRisk": 439, "seriousNumAffected": 117, "seriousNumAtRisk": 439, "otherNumAffected": 153, "otherNumAtRisk": 439}, {"id": "EG002", "title": "Open-Label Phase Sacubitril/Valsartan", "description": "All patients who received sacubitril/valsartan in the open-label phase.", "deathsNumAffected": 6, "deathsNumAtRisk": 828, "seriousNumAffected": 104, "seriousNumAtRisk": 828, "otherNumAffected": 65, "otherNumAtRisk": 828}, {"id": "EG003", "title": "Pooled Phase Sacubitril/Valsartan", "description": "All patients who received a dose of sacubitril/valsartan either in the double-blind phase or open-label phase.", "deathsNumAffected": 16, "deathsNumAtRisk": 851, "seriousNumAffected": 191, "seriousNumAtRisk": 851, "otherNumAffected": 199, "otherNumAtRisk": 851}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Coagulopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Leukocytosis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Acute left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 851}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Atrial thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 19, "numAtRisk": 851}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 18, "numAtRisk": 851}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 27, "numAtRisk": 851}]}, {"term": "Cardiac sarcoidosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Cardiac ventricular thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Congestive cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Ischaemic cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 851}]}, {"term": "Long QT syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Pulseless electrical activity", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Right ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Sinus arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Sinus tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Systolic dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Ventricular arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 851}]}, {"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Gastric disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Gastric ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Lower gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Megacolon", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Retroperitoneal haematoma", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Hypothermia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Multiple organ dysfunction syndrome", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Cardiac cirrhosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Cholangitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Hepatic cirrhosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Hepatic failure", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Liver injury", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Sarcoidosis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Clostridium difficile colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Clostridium difficile infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Corona virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Kidney infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Pseudomembranous colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Gun shot wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Subarachnoid haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Thoracic vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Anticoagulation drug level above therapeutic", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Ejection fraction decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Glomerular filtration rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Heart rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Oxygen saturation decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Transaminases increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Troponin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Failure to thrive", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Fluid overload", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Hypercalcaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 13, "numAtRisk": 851}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Hypovolaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Ketosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Lactic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Type 1 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Joint effusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Acute myeloid leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Adenocarcinoma of colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Plasma cell myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Aphasia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Cerebellar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 851}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Vascular headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Lead dislodgement", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Confusional state", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Hallucination", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Major depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Mental status changes", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Substance abuse", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 21, "numAtRisk": 851}]}, {"term": "Azotaemia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Chronic kidney disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Renal infarct", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Acute respiratory distress syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 851}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 851}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Hypoxia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Organising pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Orthopnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Pleurisy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Pleuritic pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Pulmonary infarction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Pulmonary ossification", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 851}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Accelerated hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Arterial haemorrhage", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Circulatory collapse", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 851}]}, {"term": "Extremity necrosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Hypoperfusion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 21, "numAtRisk": 851}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 851}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Peripheral ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}, {"term": "Peripheral vascular disorder", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Shock", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 851}]}, {"term": "Shock haemorrhagic", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 851}]}], "otherEvents": [{"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 36, "numAtRisk": 851}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 39, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 47, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 57, "numAtRisk": 851}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 38, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 55, "numAtRisk": 851}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 24, "numAtRisk": 851}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 65, "numAtRisk": 436}, {"groupId": "EG001", "numAffected": 71, "numAtRisk": 439}, {"groupId": "EG002", "numAffected": 33, "numAtRisk": 828}, {"groupId": "EG003", "numAffected": 97, "numAtRisk": 851}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "Novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-10-05", "uploadDate": "2019-07-19T12:25", "filename": "Prot_000.pdf", "size": 857445}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-08-20", "uploadDate": "2019-07-19T12:25", "filename": "SAP_001.pdf", "size": 529009}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "D000004656", "term": "Enalapril"}, {"id": "D000015773", "term": "Enalaprilat"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M7822", "name": "Enalapril", "asFound": "Box", "relevance": "HIGH"}, {"id": "M18330", "name": "Enalaprilat", "asFound": "Box", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}